Legend Biotech Corporation
19.27USD
+0.3700 (+1.96%)
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on LEGN.
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | 117.0M | 285.1M | 627.3M | 1.0B | 1.4B | 1.8B |
| Q1 | — | — | — | 195.0M | 305.1M | — |
| Q2 | — | — | — | 255.1M | — | — |
| Q3 | — | — | — | 272.3M | 359.9M | — |
| Q4 | — | — | — | 306.4M | 382.0M | — |
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | -2.80 | -2.94 | -.960 | -1.62 | -.010 | .683 |
| Q1 | — | — | — | -.540 | -.300 | — |
| Q2 | — | — | — | -.680 | — | — |
| Q3 | — | — | — | -.220 | .010 | — |
| Q4 | — | — |
Fiscal period: Reported, Estimated. Reported figures: Yahoo Finance (limited history). Estimates are sell-side consensus for periods that have not reported. Earnings per share are restated onto today's share basis, so a period before a stock split is comparable with the ones after it.
Revenue to net income
| — |
| -.160 |
| .090 |
| — |
Debt level and coverage